FAQ: Advanced Antibody Development with Cyagen HUGO-Ab & Biointron AbDrop

HUGO-Ab^TM: Humanized Genomic Ortholog for Antibody Development

1. What is unique about the Cyagen HUGO-Ab^TM platform?

Cyagen's HUGO-Ab^TM platform utilizes fully humanized mice engineered to produce human monoclonal antibodies. These mice have human immunoglobulin loci, allowing them to generate antibodies with human-like affinity and specificity without the need for subsequent humanization — significantly streamlining the development process.

2. Why choose transgenic mice for antibody production over other methods?

Transgenic mice offer a unique advantage by providing a humanized immune system context. This allows antibodies to undergo natural immune diversification and selection, akin to that in the human body, resulting in highly efficacious antibodies suitable for therapeutic use due to their high affinity and low immunogenicity.

3. What technological advancements does Cyagen offer for genetic modifications in HUGO-Ab^TM mice?

Cyagen employs its proprietary TurboKnockout^® gene editing technology, which enhances traditional ES cell targeting by enabling precise modifications and reducing the breeding time. This technology allows for the construction of complex genetic models, including those requiring large segment gene modifications, efficiently and accurately.

AbDrop^TM: High-throughput Droplet Based Single B Cell Screening

4. How does Biointron^’s AbDrop^TM platform enhance antibody discovery?

The AbDrop^TM platform by Biointron uses microfluidic technology to isolate and screen single B cells at high throughput. This method allows for precise control over experimental conditions and significantly reduces reagent use while speeding up the antibody discovery process by capturing a diverse array of antibody sequences from individual cells.

5. How does the AbDrop^TM technology work?

AbDrop^TM technology involves creating microdroplets that encapsulate individual plasma cells, allowing for high-throughput screening of millions of cells in a single day. This leads to rapid, efficient isolation and analysis of B cells, reducing the timeline from immunization to antibody validation.

Accelerating Antibody Drug Discovery with HUGO-Ab^TM mice & AbDrop^TM

6. What are the advantages of combining HUGO-Ab^TM mice with the AbDrop^TM platform?

Combining these technologies enhances the efficiency of humanized antibody development and discovery to as fast as 3 months. The HUGO-Ab^TM mice provide a diverse array of human-like antibodies, which the AbDrop^TM platform can rapidly screen at the single-cell level. This synergy accelerates the identification and production of potent, specific antibodies, and covers a broader range of epitopes, increasing the likelihood of discovering effective therapeutic antibodies.

7. What makes the combined platform of Cyagen and Biointron ideal for antibody development?

The combination of Cyagen^'s genetically engineered mice and Biointron's microfluidic screening offers a comprehensive approach to antibody development. This integrated platform ensures a rapid and robust discovery process, from antigen-specific immunization through to the screening of high-affinity, fully human antibodies that are ready for therapeutic application.

About Cyagen Biosciences

Founded in 2006, Cyagen Biosciences (“Cyagen”) is a global provider of genetically modified rodent models and innovative one-stop cell and gene therapy solutions for research and development, including: disease model development, AAV discovery, drug efficacy studies, and more. Cyagen serves global research from discovery to the clinic, having established its presence as an innovative CRO company that accelerates new drug development. Cyagen remains at the forefront of the gene-edited animal model industry: from in-stock models, custom models, breeding, to phenotypic analysis, it offers comprehensive solutions to meet clients' needs in basic research and new drug development. Moreover, Cyagen Biosciences continuously expands its service capabilities to maintain its cutting-edge technical advancements, establishing CRO service platforms for: preclinical pharmacology and pharmacodynamics with a focus on cancer research, ophthalmic disease gene therapy research, and antibody discovery capabilities featuring fully humanized antibody mice.

Cyagen currently has over 900 employees and multiple facilities with a total scale of over 40,000 square meters, including our US headquarters in Santa Clara, California, and additional locations in Japan and China. Cyagen Biosciences has established extensive cooperations with scientists and enterprises in over 100 countries worldwide, with its products and technologies being directly applied in more than 10,000 academic papers, including many published in the three major journals of CNS (Cell, Nature, Science). From its foundation in animal model development, to implementation of AI-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug research and development with our unique offering of models, data, algorithms, and services.

About Biointron

Founded in 2012, Biointron is an ISO 9001:2015 certified CRO specializing in antibody discovery, optimization, and expression, serving over 1,500 biotech and pharma companies globally.
Offers a comprehensive suite of services for antibody research, including discovery, screening, sequencing, humanization, and affinity maturation.
Holds global sublicensing rights for ECACC's CHO-K1 and has developed the CHOK1BN cell line, facilitating partners' projects to enter international clinical trials.
Visit www.biointron.com or contact info@biointron.com for more information on Biointron's services and partnerships.